My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novavax, Inc. - Common Stock (NQ:NVAX)

7.780 -0.410 (-5.01%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Novavax Stock Rips Nearly 20% Pre-Market After FDA Approves Its COVID-19 Vaccine Nuvaxovid ↗

May 19, 2025

Novavax CEO John C. Jacobs called the approval a “significant milestone” as the company seeks to make its protein-based COVID-19 vaccine commercially available.

Via Stocktwits

Topics Government Stocks

These stocks are moving in today's pre-market session ↗

May 19, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

May 19, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Uncovering Potential: Novavax's Earnings Preview ↗

May 07, 2025

Via Benzinga

US Stocks Likely To Open Lower After Moody's Downgrade: 'Bear Market Isn't Fully Recovered Yet, But It Is Close,' Says Expert ↗

May 19, 2025

U.S. stock futures dipped on Monday after closing higher for the day and the week on Friday. Futures were trading lower in premarket.

Via Benzinga

Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny ↗

May 19, 2025

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions...

Via Benzinga

Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Moves ↗

May 18, 2025

The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.

Via Stocktwits

Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets ↗

May 10, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why ↗

May 08, 2025

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations.

Via Benzinga

Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana? ↗

May 08, 2025

D-Wave Quantum Inc. (NYSE:QBTS), Asset Entities, Inc. (NASDAQ:ASST), Alphabet, Inc.

Via Benzinga

Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated ↗

May 08, 2025

The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 08, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline ↗

April 29, 2025

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting...

Via Benzinga

Topics Government

Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes ↗

April 27, 2025

Optimism was tempered by a Wall Street Journal report on Friday, which said federal regulators had asked Novavax to conduct another randomized clinical trial of its COVID-19 vaccine.

Via Stocktwits

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps ↗

April 23, 2025

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision.

Via Benzinga

Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday ↗

April 23, 2025

Via Benzinga

Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers ↗

April 23, 2025

The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data.

Via Stocktwits

Topics Government

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study ↗

April 15, 2025

Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.

Via Benzinga

Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling ↗

April 10, 2025

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 10, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 10, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

April 08, 2025

Via The Motley Fool

Topics Cannabis Government Law Enforcement

Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst ↗

April 03, 2025

Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.

Via Benzinga

Topics World Trade

Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful ↗

April 02, 2025

Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall...

Via Stocktwits

FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine ↗

April 02, 2025

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

Via Benzinga

Moderna, Novavax Shares Are Tumbling Monday: What's Going On? ↗

March 31, 2025

Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.